Bennett J M, Silber R, Ezdinli E, Levitt M, Oken M, Bakemeier R F, Bailar J C, Carbone P P
Cancer Treat Rep. 1978 Sep;62(9):1367-9.
Twenty-seven patients with far-advanced multiple myeloma, resistant to standard agents, were treated with either adriamycin (eight patients) or bleomycin (19 patients). Adriamycin was given iv at a dose of 60 mg/m2 every 3 weeks and bleomycin was administered im at a dose of 15 mg/m2 weekly. Drug toxicity was modest. One partial response was seen with each agent, both occurring in "good-risk" patients.
27例对标准治疗药物耐药的晚期多发性骨髓瘤患者，分别接受阿霉素治疗（8例）或博来霉素治疗（19例）。阿霉素静脉注射，剂量为60mg/m²，每3周一次；博来霉素肌肉注射，剂量为15mg/m²，每周一次。药物毒性较轻。两种药物各出现1例部分缓解，均发生在“低危”患者中。
